ENTX Entera Bio Ltd.
Biological Products, (No Diagnostic Substances) · Nasdaq · SEC CIK 1638097 · Fiscal year ends 12/31
Financial factors as of 2025-12-31 (2025Q4), TTM = sum of the last four quarters
Growth
TTM revenue YoY-76.8%
TTM net income YoY-19.9%
TTM EPS YoY0.0%
Revenue 3-yr CAGR-32.1%
Net income 3-yr CAGR—
Margins
Gross margin0.0%
Operating margin-27,450.0%
Net margin-27,235.7%
FCF margin-17,802.4%
EBITDA margin-27,378.6%
Returns
ROE-108.0%
ROA-90.1%
ROIC (approx.)-341.6%
Asset turnover0.00x
Leverage & solvency
Liabilities / assets18.1%
Debt / equity0.00x
Current ratio6.94x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.64x
Accruals ratio-32.1%
Payout ratio—
Capex / revenue254.8%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | $42,000 | $181,000 |
| Cost of revenue | $42,000 | $172,000 |
| Gross profit | $0 | $9,000 |
| R&D expense | $6.00M | $4.50M |
| SG&A expense | $398,000 | $340,000 |
| Operating income | -$11.53M | -$9.59M |
| Pretax income | -$11.44M | -$9.53M |
| Income tax | $0 | $14,000 |
| Net income | -$11.44M | -$9.54M |
| EBITDA | -$11.50M | -$9.54M |
| EPS (basic) | 0.25 | 0.25 |
| EPS (diluted) | 0.25 | 0.25 |
| Weighted avg. shares (diluted) | 46.19M | 37.65M |
| Balance sheet | ||
| Cash & equivalents | $7.11M | $8.74M |
| Receivables | $0 | $126,000 |
| Current assets | $15.30M | $8.97M |
| PP&E, net | $134,000 | $57,000 |
| Total assets | $15.99M | $9.39M |
| Current liabilities | $2.20M | $1.18M |
| Total liabilities | $2.89M | $1.31M |
| Shareholders' equity | $13.10M | $8.08M |
| Shares outstanding | 46.18M | 38.84M |
| Cash flow statement | ||
| Operating cash flow | -$7.37M | -$6.82M |
| Capital expenditure | $107,000 | $3,000 |
| Free cash flow | -$7.48M | -$6.82M |
| Investing cash flow | -$107,000 | -$3,000 |
| Financing cash flow | $13.71M | $4.48M |
| Depreciation & amortization | $30,000 | $46,000 |
| Stock-based compensation | $2.75M | $2.56M |
Free plan shows the latest 2 periods; Pro shows all 10 🔒
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.